SLC5A2 and cardiomyopathy: SGLT2 inhibitors enhanced AMPK and SIRT1 activation, leading to a reduction in oxidative stress, normalization of mitochondrial structure and function, suppression of inflammation, minimization of coronary microvascular injury, improved contractile performance, and attenuation of cardiomyopathy development, as demonstrated in animal models [57].